Respiratory syncytial virus vaccine adjuvanted - GSK
Alternative Names: AREXVY; Arexvy; GSK-3844766; GSK-3844766A; Respiratory syncytial virus vaccine, adjuvanted - GlaxoSmithKline; RSV vaccine, Adjuvanted - GSK; RSV_PreF3 Vaccine; RSVPreF3 OA; RSVPreF3 OA vaccineLatest Information Update: 19 Jul 2024
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Respiratory syncytial virus vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Respiratory syncytial virus infections
Most Recent Events
- 16 Jul 2024 The National Advisory Committee on Immunization (NACI) strongly recommends AREXVY for Respiratory syncytial virus infections (In adults, In the elderly, Prevention)
- 07 Jun 2024 The US FDA approves sBLA for respiratory syncytial virus vaccine adjuvanted for Respiratory syncytial virus infections (In adults aged 50-59, Prevention)
- 07 May 2024 GlaxoSmithKline completes a phase-III trial in Respiratory syncytial virus infections (Combination therapy, Prevention) in USA, Belgium, Poland, Spain (IM) (NCT05879107) (EudraCT2022-501988-40-00)